Booking Holdings vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 71)

Booking Holdings

LeaderConsumer Retail

Enterprise

Norwalk CT online travel (NASDAQ: BKNG) at $23.74B 2024 revenue (+11%), $166B gross bookings; $20B buyback authorized Jan 2025, 10% dividend increase, Booking.com dominant in European accommodations competing with Expedia and Airbnb.

AI VisibilityBeta
Overall Score
B71
Category Rank
#258 of 290
AI Consensus
65%
Trend
stable
Per Platform
ChatGPT
66
Perplexity
76
Gemini
77

About

Booking Holdings Inc. is a Norwalk, Connecticut-based online travel platform — publicly traded on NASDAQ (NASDAQ: BKNG) as an S&P 500 Consumer Discretionary component — operating the world's largest portfolio of online travel brands including Booking.com (global accommodations leader), Priceline (US discount travel), Agoda (Asia-Pacific travel), KAYAK (metasearch), OpenTable (restaurant reservations), and Rentalcars.com across 220+ countries and territories through approximately 24,800 employees. In fiscal year 2024, Booking Holdings reported $23.74 billion in revenue (up 11% year-over-year), $5.88 billion in net income, and $166 billion in gross bookings — with Q4 2024 room nights growing 13% and gross bookings up 17% year-over-year. The company maintains a market capitalization exceeding $167 billion as of 2025. In January 2025, Booking Holdings authorized a $20 billion stock repurchase program and increased its quarterly dividend 10% to $9.60 per share, reflecting strong free cash flow generation. CEO Glenn Fogel has led the company since 2017, overseeing both pandemic recovery and the subsequent travel demand surge. Booking.com's accommodation inventory of millions of properties (hotels, vacation rentals, apartments, villas) across 220+ countries represents the broadest accommodation distribution platform in the global travel market.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

71
Overall Score
90
#258
Category Rank
#9
65
AI Consensus
60
stable
Trend
stable
66
ChatGPT
99
76
Perplexity
99
77
Gemini
83
78
Claude
96
67
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.